We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Citi Drops Gun Policy After Trump Accuses Banks of Discriminating The president has fueled allegations that banks discriminate on political grounds. Energize Capital Raises New Climate Fund With Help ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

On TipRanks, RGEN has a Strong Buy consensus based on 18 Buy, 2 Hold and 1 Sell rating. Its highest price target is $958. RGEN stock’s consensus price target is $803.42 implying an 32.71% upside ...

The S&P 500 (^GSPC) logged its best May since 1990 and its best month since Nov. 2023, rising over 6%, while the Dow (^DJI) ...